Bi-weekly: Thursdays, 12 pm EDT/EST, 9 am PT/PST, 5 pm BST/BDT, 6 pm CEST/CET
https://dfci.zoom.us/webinar/register/WN_m7JJaw52T8yZYt8-ykL6UQ
Some seminars were recorded and accessible for a limited time on our youtube channel.
Upcoming Speakers
Phenotypic discovery and optimization of TRIM21-recruiting molecular glue degraders.
Dr. Steven M. Corsello is an Assistant Professor of Medicine (Oncology) at Stanford University, with a courtesy appointment in Chemical and Systems Biology. As a physician-scientist, his lab operates at the intersection of functional genomics and chemical biology, aiming to advance novel molecular mechanisms of cancer inhibition toward clinical use. He received his AB in Biochemical Sciences from Harvard University and his MD from Harvard Medical School, followed by residency training in Internal Medicine at Massachusetts General Hospital and subspecialty training in medical oncology at the Dana-Farber Cancer Institute. He founded the Drug Repurposing Hub—a unique, publicly available collection of over 6,000 existing drugs—which powers the PRISM Drug Repurposing Screen, identifying compounds with unexpected selective anti-cancer activity. Dr. Corsello’s work has been recognized with the Damon Runyon Clinical Investigator Award, the American Society of Clinical Oncology Young Investigator Award, and a National Cancer Institute Career Development Award.
Anthony Rullo
McMaster University
Dual Covalent Stabilization of Ternary Complexes for "Induced Proximity" at the Cell Surface.
The focuses of the Rullo Translational Chemical Biology research program are directed at integrating the tools of organic chemistry physical biochemistry and immunobiology to develop new molecular approaches capable of interrogating and modulating immune recognition of disease. This research program is founded within the scientific environment of the Center for Discovery in Cancer Research (CDCR) and McMaster Immunology Research Center (MIRC). Prof. Rullo’s chemical biological scientific training and experience, encompasses the development of chemical strategies and probes to study immunologically relevant biomolecular interactions and modulate the function of macromolecules such as lectins and antibodies. This work also founds the development of new synthetic tumor immunotherapeutic tools including covalent immune recruiting molecules. After obtaining his undergraduate degree in Biochemistry at McMaster University, Prof. Rullo began studying structural carbohydrate chemistry and polysaccharide vaccine development with Mario A. Monteiro during his master’s studies at the University of Guelph. As a doctoral student under the supervision of Mark Nitz at the University of Toronto, he developed fluorescent chemical probes of complex glycosaminoglycan binding interactions, in addition to new carbohydrate directed affinity labeling bio-conjugation strategies. Dr. Rullo conducted his postdoctoral research in David A. Spiegel’s laboratory at Yale, working to develop new bi-functional small molecule based immunotherapeutic approaches. This yielded the discovery of first in class antibody recruiting molecules capable of targeting highly metastatic cancers in vivo. He currently serves as the scientific founder and CSO of BICOVA Therapeutics, a new biotech company spun out of McMaster University in 2024.
February 5th, 2026
Host: Hubert Huang
Michelle Arkin
UCSF
Molecular glues for native protein-protein interactions.
Michelle Arkin is a chemical biologist, Executive Director of the Small Molecule Discovery Center, and Vice Dean of Research Technology and Entrepreneurship in the School of Pharmacy at UCSF. Her research focuses on developing methods and molecules that target currently ‘undruggable proteins,’ including protein-protein interactions and dynamic or intrinsically disordered proteins. For this work, she was recognized by the 2024 American Chemical Society (ACS) Cope Scholar Award, 2024 ACS/Biochemistry Gordon Hammes Lecturer Award, and 2025 Harrison Howe Award (Rochester section of the ACS). Prior to UCSF, Michelle was a scientist at Sunesis Pharmaceuticals, where she helped discover small molecule inhibitors of IL-2/IL-2R and LFA/ICAM (the anti-inflammatory drug lifitegrast, marketed by Novartis). She serves on the advisory boards for several pharmaceutical companies and is a co-founder of Elgia Tx, Ambagon Tx, ResNovas Tx, and BNM Oncology.
.jpeg)
February 19th, 2026
Host: Katherine Donovan / Mikolaj Slabicki
Chase Suiter
University of Washington
Multiplex design and discovery of proximity handles for programmable proteome editing.
Chase Suiter develops technologies to profile and program protein degradation. As part of his graduate work, he combined computational protein design and high-throughput cellular screening methods to discover “proximity handles” that enable programmable proteome editing using effectors from the UPS and autophagy pathways. His long-term goal is to develop computationally designed therapeutics to treat complex human disease.
Carles Galdeano
University of Barcelona
From Exploiting Binding Sites on E3 ligases to Developing Allosteric Modulators of the FBW7 E3 Ligase.
Dr Carles Galdeano is currently an Associate Professor at the University of Barcelona. He obtained his PhD in medicinal chemistry at the University of Barcelona. After that, he spent three years post-doc in Alessio Ciulli’s lab (first at the University of Cambridge and later at the University of Dundee) where they developed the first potent VHL ligands described. His postdoctoral discoveries represented a breakthrough in the PROTACs field. In 2015, he returned to the University of Barcelona to work in collaboration with Prof Barril until 2019, when he started his independent research group. Dr Galdeano is also co-founder of Oniria Therapeutics. His lab is interested in expanding the druggable proteome since most proteins are still considered undruggable for conventional drug discovery approaches.